Clinical Trial Update: Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating anti-CD19 CAR-T cell therapy for refractory systemic lupus erythematosus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Anti-CD19 CAR-T cell therapy (CD19-targeted chimeric antigen receptor T cells)

Snippet

Sponsor: The Children's Hospital of Zhejiang University School of Medicine | Conditions: Systemic Lupus Erythematosus, CAR-T Cell Therapy | Phase 1 | Status: ACTIVE_NOT_RECRUITING